34 related articles for article (PubMed ID: 22394115)
1. Altered DNA binding and amplification of human breast cancer suppressor gene BRCA1 induced by a novel antitumor compound, [Ru(η(6)-p-phenylethacrynate)Cl(2)(pta)].
Chakree K; Ovatlarnporn C; Dyson PJ; Ratanaphan A
Int J Mol Sci; 2012 Oct; 13(10):13183-202. PubMed ID: 23202946
[TBL] [Abstract][Full Text] [Related]
2. A unique non-catenane interlocked self-assembled supramolecular architecture and its photophysical properties.
Vajpayee V; Song YH; Cook TR; Kim H; Lee Y; Stang PJ; Chi KW
J Am Chem Soc; 2011 Dec; 133(49):19646-9. PubMed ID: 22085308
[TBL] [Abstract][Full Text] [Related]
3. Enzymatic Approach to the Synthesis of Enantiomerically Pure Hydroxy Derivatives of 1,3,5-Triaza-7-phosphaadamantane.
Kwiatkowska M; Błaszczyk J; Sieroń L; Kiełbasiński P
J Org Chem; 2021 Jul; 86(13):8556-8562. PubMed ID: 34137610
[TBL] [Abstract][Full Text] [Related]
4. Carcinogenicity of anthracene, 2-bromopropane, butyl methacrylate, and dimethyl hydrogen phosphite.
Cattley RC; Kromhout H; Sun M; Tokar EJ; Abdallah MA; Bauer AK; Broadwater KR; Campo L; Corsini E; Houck KA; Ichihara G; Matsumoto M; Morais S; Mráz J; Nomiyama T; Ryan K; Shen H; Toyoda T; Vähäkangas K; Yakubovskaya MG; Yu IJ; DeBono NL; de Conti A; El Ghissassi F; Madia F; Mattock H; Pasqual E; Suonio E; Wedekind R; Benbrahim-Tallaa L; Schubauer-Berigan MK
Lancet Oncol; 2023 May; 24(5):431-432. PubMed ID: 36966774
[No Abstract] [Full Text] [Related]
5. Fluorescent half-sandwich iridium picolinamidate complexes for in-cell visualization.
Bose S; Nguyen HD; Ngo AH; Do LH
J Inorg Biochem; 2022 Sep; 234():111877. PubMed ID: 35671630
[TBL] [Abstract][Full Text] [Related]
6. In vitro effects of binuclear (η (6)-p-cymene)ruthenium(II) complex containing bridging bis(nicotinate)-polyethylene glycol ester ligand on differentiation pathways of murine Th lymphocytes activated by T cell mitogen.
Momcilovic M; Eichhorn T; Blazevski J; Schmidt H; Kaluđerović GN; Stosic-Grujicic S
J Biol Inorg Chem; 2015 Apr; 20(3):575-83. PubMed ID: 25827592
[TBL] [Abstract][Full Text] [Related]
7. Gold-phosphine-porphyrin as potential metal-based theranostics.
Tasan S; Licona C; Doulain PE; Michelin C; Gros CP; Le Gendre P; Harvey PD; Paul C; Gaiddon C; Bodio E
J Biol Inorg Chem; 2015 Jan; 20(1):143-154. PubMed ID: 25476859
[TBL] [Abstract][Full Text] [Related]
8. Influence of the π-coordinated arene on the anticancer activity of ruthenium(II) carbohydrate organometallic complexes.
Hanif M; Meier SM; Nazarov AA; Risse J; Legin A; Casini A; Jakupec MA; Keppler BK; Hartinger CG
Front Chem; 2013; 1():27. PubMed ID: 24790955
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxicity, apoptosis, cell cycle arrest, reactive oxygen species, mitochondrial membrane potential, and Western blotting analysis of ruthenium(II) complexes.
Lin GJ; Jiang GB; Xie YY; Huang HL; Liang ZH; Liu YJ
J Biol Inorg Chem; 2013 Dec; 18(8):873-82. PubMed ID: 23989405
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and characterization of a new class of anti-angiogenic agents based on ruthenium clusters.
Nazarov AA; Baquié M; Nowak-Sliwinska P; Zava O; van Beijnum JR; Groessl M; Chisholm DM; Ahmadi Z; McIndoe JS; Griffioen AW; van den Bergh H; Dyson PJ
Sci Rep; 2013; 3():1485. PubMed ID: 23508096
[TBL] [Abstract][Full Text] [Related]
11. Osmium(II)--versus ruthenium(II)--arene carbohydrate-based anticancer compounds: similarities and differences.
Hanif M; Nazarov AA; Hartinger CG; Kandioller W; Jakupec MA; Arion VB; Dyson PJ; Keppler BK
Dalton Trans; 2010 Aug; 39(31):7345-52. PubMed ID: 20601976
[TBL] [Abstract][Full Text] [Related]
12. Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents.
Peacock AF; Sadler PJ
Chem Asian J; 2008 Nov; 3(11):1890-9. PubMed ID: 18712745
[TBL] [Abstract][Full Text] [Related]
13. Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes.
Yan YK; Melchart M; Habtemariam A; Sadler PJ
Chem Commun (Camb); 2005 Oct; (38):4764-76. PubMed ID: 16193110
[TBL] [Abstract][Full Text] [Related]
14. Anthracene-tethered ruthenium(II) arene complexes as tools to visualize the cellular localization of putative organometallic anticancer compounds.
Nazarov AA; Risse J; Ang WH; Schmitt F; Zava O; Ruggi A; Groessl M; Scopelitti R; Juillerat-Jeanneret L; Hartinger CG; Dyson PJ
Inorg Chem; 2012 Mar; 51(6):3633-9. PubMed ID: 22394115
[TBL] [Abstract][Full Text] [Related]
15. Tuning the hydrophobicity of ruthenium(II)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy.
Scolaro C; Chaplin AB; Hartinger CG; Bergamo A; Cocchietto M; Keppler BK; Sava G; Dyson PJ
Dalton Trans; 2007 Nov; (43):5065-72. PubMed ID: 17992291
[TBL] [Abstract][Full Text] [Related]
16. From hydrolytically labile to hydrolytically stable Ru(II)-arene anticancer complexes with carbohydrate-derived co-ligands.
Hanif M; Meier SM; Kandioller W; Bytzek A; Hejl M; Hartinger CG; Nazarov AA; Arion VB; Jakupec MA; Dyson PJ; Keppler BK
J Inorg Biochem; 2011 Feb; 105(2):224-31. PubMed ID: 21194622
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
